174 related articles for article (PubMed ID: 23353808)
1. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation.
Nguyen TH; Tan A; Santos L; Ngo D; Edwards GA; Porter CJ; Prestidge CA; Boyd BJ
J Control Release; 2013 Apr; 167(1):85-91. PubMed ID: 23353808
[TBL] [Abstract][Full Text] [Related]
2. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.
Tan A; Davey AK; Prestidge CA
Pharm Res; 2011 Sep; 28(9):2273-87. PubMed ID: 21560021
[TBL] [Abstract][Full Text] [Related]
3. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs.
Tan A; Simovic S; Davey AK; Rades T; Prestidge CA
J Control Release; 2009 Feb; 134(1):62-70. PubMed ID: 19013488
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the oral bioavailability of simvastatin with silica-lipid hybrid particles: The effect of supersaturation and silica geometry.
Meola TR; Schultz HB; Peressin KF; Prestidge CA
Eur J Pharm Sci; 2020 Jul; 150():105357. PubMed ID: 32446169
[TBL] [Abstract][Full Text] [Related]
5. Pluronic-Functionalized Silica-Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases.
Rao S; Richter K; Nguyen TH; Boyd BJ; Porter CJ; Tan A; Prestidge CA
Mol Pharm; 2015 Dec; 12(12):4424-33. PubMed ID: 26523928
[TBL] [Abstract][Full Text] [Related]
6. In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.
Song WH; Yeom DW; Lee DH; Lee KM; Yoo HJ; Chae BR; Song SH; Choi YW
Arch Pharm Res; 2014 May; 37(5):626-35. PubMed ID: 23852645
[TBL] [Abstract][Full Text] [Related]
7. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations.
Yasmin R; Tan A; Bremmell KE; Prestidge CA
J Pharm Sci; 2014 Sep; 103(9):2950-2959. PubMed ID: 24585389
[TBL] [Abstract][Full Text] [Related]
8. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.
Guzmán HR; Tawa M; Zhang Z; Ratanabanangkoon P; Shaw P; Gardner CR; Chen H; Moreau JP; Almarsson O; Remenar JF
J Pharm Sci; 2007 Oct; 96(10):2686-702. PubMed ID: 17518357
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
10. Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate.
Schultz HB; Joyce P; Thomas N; Prestidge CA
Pharm Res; 2020 Mar; 37(4):77. PubMed ID: 32236761
[TBL] [Abstract][Full Text] [Related]
11. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
Dening TJ; Rao S; Thomas N; Prestidge CA
Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
[TBL] [Abstract][Full Text] [Related]
12. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.
Ghorab DM; Amin MM; Khowessah OM; Tadros MI
Drug Deliv; 2011; 18(7):523-35. PubMed ID: 21793779
[TBL] [Abstract][Full Text] [Related]
13. A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants.
Meola TR; Abuhelwa AY; Joyce P; Clifton P; Prestidge CA
Drug Deliv Transl Res; 2021 Jun; 11(3):1261-1272. PubMed ID: 32918160
[TBL] [Abstract][Full Text] [Related]
14. Effect of eye pigmentation on transscleral drug delivery.
Cheruvu NP; Amrite AC; Kompella UB
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):333-41. PubMed ID: 18172110
[TBL] [Abstract][Full Text] [Related]
15. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems.
Tan A; Simovic S; Davey AK; Rades T; Boyd BJ; Prestidge CA
Mol Pharm; 2010 Apr; 7(2):522-32. PubMed ID: 20063867
[TBL] [Abstract][Full Text] [Related]
16. Mesoporous carbon with spherical pores as a carrier for celecoxib with needle-like crystallinity: improve dissolution rate and bioavailability.
Zhu W; Zhao Q; Sun C; Zhang Z; Jiang T; Sun J; Li Y; Wang S
Mater Sci Eng C Mater Biol Appl; 2014 Jun; 39():13-20. PubMed ID: 24863191
[TBL] [Abstract][Full Text] [Related]
17. Supersaturated Silica-Lipid Hybrid Oral Drug Delivery Systems: Balancing Drug Loading and In Vivo Performance.
Schultz HB; Kovalainen M; Peressin KF; Thomas N; Prestidge CA
J Pharmacol Exp Ther; 2019 Sep; 370(3):742-750. PubMed ID: 30552294
[TBL] [Abstract][Full Text] [Related]
18. Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug.
Morgen M; Bloom C; Beyerinck R; Bello A; Song W; Wilkinson K; Steenwyk R; Shamblin S
Pharm Res; 2012 Feb; 29(2):427-40. PubMed ID: 21863477
[TBL] [Abstract][Full Text] [Related]
19. Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.
Nasr M
AAPS PharmSciTech; 2013 Jun; 14(2):719-26. PubMed ID: 23543607
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids.
Schultz HB; Wignall AD; Thomas N; Prestidge CA
Int J Pharm; 2020 May; 582():119264. PubMed ID: 32278053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
